JP6522387B2 - ハイドロゲル含有化粧料 - Google Patents
ハイドロゲル含有化粧料 Download PDFInfo
- Publication number
- JP6522387B2 JP6522387B2 JP2015067361A JP2015067361A JP6522387B2 JP 6522387 B2 JP6522387 B2 JP 6522387B2 JP 2015067361 A JP2015067361 A JP 2015067361A JP 2015067361 A JP2015067361 A JP 2015067361A JP 6522387 B2 JP6522387 B2 JP 6522387B2
- Authority
- JP
- Japan
- Prior art keywords
- skin cosmetic
- hydrogel
- skin
- water
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002537 cosmetic Substances 0.000 title claims description 79
- 239000000017 hydrogel Substances 0.000 title claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000002502 liposome Substances 0.000 claims description 26
- 150000002632 lipids Chemical class 0.000 claims description 16
- 108010010803 Gelatin Proteins 0.000 claims description 15
- 229920000159 gelatin Polymers 0.000 claims description 15
- 239000008273 gelatin Substances 0.000 claims description 15
- 235000019322 gelatine Nutrition 0.000 claims description 15
- 235000011852 gelatine desserts Nutrition 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 13
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 10
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 210000002826 placenta Anatomy 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 5
- 102000016942 Elastin Human genes 0.000 claims description 5
- 108010014258 Elastin Proteins 0.000 claims description 5
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 5
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 5
- 229920002079 Ellagic acid Polymers 0.000 claims description 5
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 5
- 229940024606 amino acid Drugs 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 229960000271 arbutin Drugs 0.000 claims description 5
- 229940106189 ceramide Drugs 0.000 claims description 5
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 5
- 229960005188 collagen Drugs 0.000 claims description 5
- 229920002549 elastin Polymers 0.000 claims description 5
- 229960002852 ellagic acid Drugs 0.000 claims description 5
- 235000004132 ellagic acid Nutrition 0.000 claims description 5
- 229960004337 hydroquinone Drugs 0.000 claims description 5
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 claims description 5
- 229960004705 kojic acid Drugs 0.000 claims description 5
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 claims description 5
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 5
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 5
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 5
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 claims description 5
- 229960003471 retinol Drugs 0.000 claims description 5
- 235000020944 retinol Nutrition 0.000 claims description 5
- 239000011607 retinol Substances 0.000 claims description 5
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 5
- 229960000401 tranexamic acid Drugs 0.000 claims description 5
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 55
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 20
- 229940014259 gelatin Drugs 0.000 description 14
- 230000035699 permeability Effects 0.000 description 12
- 238000004108 freeze drying Methods 0.000 description 11
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 8
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 8
- 229940126864 fibroblast growth factor Drugs 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 150000001982 diacylglycerols Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940042880 natural phospholipid Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000002123 temporal effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- GFAZGHREJPXDMH-UHFFFAOYSA-N 1,3-dipalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCC GFAZGHREJPXDMH-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000008393 encapsulating agent Substances 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229940074045 glyceryl distearate Drugs 0.000 description 2
- 102000009543 guanyl-nucleotide exchange factor activity proteins Human genes 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- DRAWQKGUORNASA-UHFFFAOYSA-N (2-hydroxy-3-octadec-9-enoyloxypropyl) octadec-9-enoate Chemical compound CCCCCCCCC=CCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCC=CCCCCCCCC DRAWQKGUORNASA-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- -1 and for example Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940086541 peg-12 glyceryl dimyristate Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Description
(1)皮膚美容成分を担持させたハイドロゲル、及びリポソーム構成脂質を含む、皮膚化粧料。
(2)皮膚美容成分を担持させたハイドロゲルがリポソーム中に封入されている、上記(1)記載の皮膚化粧料。
(3)ハイドロゲルが架橋ゼラチンで構成される、上記(1)又は(2)記載の皮膚化粧料。
(4)皮膚美容成分が成長因子を含む、上記(1)〜(3)のいずれか記載の皮膚化粧料。
(5)リポソーム構成脂質がPEG鎖を含む合成脂質である、上記(1)〜(4)のいずれか記載の皮膚化粧料。
(6)使用前に水で溶解する凍結乾燥形態である、上記(1)〜(5)のいずれか記載の皮膚化粧料。
(7)溶解するための水に更なる有効成分が含まれる、上記(6)記載の皮膚化粧料。
(8)更なる有効成分がヒアルロン酸、コラーゲン、アミノ酸、ビタミン、プラセンタエキス、セラミド、アルブチン、レチノール、エラスチン、エラグ酸、ハイドロキノン、トラネキサム酸、コウジ酸、及びピロロキノリンキノン(PQQ)からなる群から選択される、上記(7)記載の皮膚化粧料。
(9)上記(6)記載の凍結乾燥形態の皮膚化粧料と、これを溶解するための水とを別個の容器に入れて提供する、皮膚化粧料用時調製用キット。
(10)溶解するための水がヒアルロン酸、コラーゲン、アミノ酸、ビタミン、プラセンタエキス、セラミド、アルブチン、レチノール、エラスチン、エラグ酸、ハイドロキノン、トラネキサム酸、コウジ酸、及びピロロキノリンキノン(PQQ)からなる群から選択される更なる有効成分が溶解した水溶液である、上記(9)記載のキット。
EGFの皮膚透過性評価
各被験物質を、以下の最終濃度となるようにリン酸緩衝生理食塩水(PBS)で希釈した。
(1)EGF(rh-OLIGOPEPTIDE-1)(2μg/mL)
(2)EGF(2μg/mL)+架橋型ゼラチン(10%)
(3)EGF(2μg/mL)+ナノソーム用カプセル化剤(PEG-12 GDM)(2%)
(4)EGF(2μg/mL)+架橋型ゼラチン(10%)+ナノソーム用カプセル化剤(2%)
凍結乾燥による安定化効果の確認
凍結乾燥処理により、EGF(rh-OLIGOPEPTIDE-1)及びFGF(rh-OLIGOPEPTIDE-11)の経時的安定性が向上することを確認した。実施例1と同様、EGFおよびFGFをそれぞれリン酸緩衝生理食塩水(PBS)中に100mg/mLの濃度で調製し、凍結乾燥を行うか、または凍結乾燥をせずに水溶液の状態で常温で保存し、残存量を測定した。残存活性はHela細胞のMTS法(Cell Titer96(登録商標) Aqueous One Solution Cell Proliferation Assay(プロメガ社)を使用)により評価した。結果を図1に示す。
Claims (7)
- 皮膚美容成分を担持させたハイドロゲルがリポソーム中に封入されている皮膚化粧料であって、該皮膚美容成分が上皮細胞増殖因子EGFであり、該ハイドロゲルが架橋ゼラチンで構成されている、上記皮膚化粧料。
- 上記リポソームがPEG鎖を含む合成脂質で構成されている、請求項1記載の皮膚化粧料。
- 使用前に水で溶解する凍結乾燥形態である、請求項1又は2記載の皮膚化粧料。
- 溶解するための水に更なる有効成分が含まれる、請求項3記載の皮膚化粧料。
- 更なる有効成分がヒアルロン酸、コラーゲン、アミノ酸、ビタミン、プラセンタエキス、セラミド、アルブチン、レチノール、エラスチン、エラグ酸、ハイドロキノン、トラネキサム酸、コウジ酸、及びピロロキノリンキノン(PQQ)からなる群から選択される、請求項4記載の皮膚化粧料。
- 請求項3記載の凍結乾燥形態の皮膚化粧料と、これを溶解するための水とを別個の容器に入れて提供する、皮膚化粧料用時調製用キット。
- 溶解するための水がヒアルロン酸、コラーゲン、アミノ酸、ビタミン、プラセンタエキス、セラミド、アルブチン、レチノール、エラスチン、エラグ酸、ハイドロキノン、トラネキサム酸、コウジ酸、及びピロロキノリンキノン(PQQ)からなる群から選択される更なる有効成分が溶解した水溶液である、請求項6記載のキット。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015067361A JP6522387B2 (ja) | 2015-03-27 | 2015-03-27 | ハイドロゲル含有化粧料 |
PCT/JP2016/059983 WO2016158883A1 (ja) | 2015-03-27 | 2016-03-28 | ハイドロゲル含有化粧料 |
CN201680016786.3A CN107405279A (zh) | 2015-03-27 | 2016-03-28 | 含有水凝胶的化妆品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015067361A JP6522387B2 (ja) | 2015-03-27 | 2015-03-27 | ハイドロゲル含有化粧料 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016185933A JP2016185933A (ja) | 2016-10-27 |
JP6522387B2 true JP6522387B2 (ja) | 2019-05-29 |
Family
ID=57004266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015067361A Active JP6522387B2 (ja) | 2015-03-27 | 2015-03-27 | ハイドロゲル含有化粧料 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP6522387B2 (ja) |
CN (1) | CN107405279A (ja) |
WO (1) | WO2016158883A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3473236B1 (en) * | 2017-10-17 | 2021-04-28 | LvmH Recherche | Microgels for the delivery of cosmetic active organic substances |
CN110354003B (zh) * | 2019-07-08 | 2022-05-27 | 广州贝研生物科技有限公司 | 传明酸作为冻干粉赋形剂的应用及冻干工艺 |
JP6805385B1 (ja) * | 2020-08-31 | 2020-12-23 | ジェイ−ネットワーク,インコーポレイテッド | 表皮内の保湿関連物質の発現増強剤 |
JPWO2022225046A1 (ja) * | 2021-04-23 | 2022-10-27 | ||
KR102628359B1 (ko) * | 2023-10-12 | 2024-01-24 | 주식회사 마이센 | 스몰 리포좀 액정 유화 화장료 조성물, 및 이를 포함하는 미백, 주름 개선 및 보습용 다기능성 화장품 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02111799A (ja) * | 1988-10-20 | 1990-04-24 | Denki Kagaku Kogyo Kk | コロニー刺激因子を含有するゼラチンマイクロスフェアー |
SE9003706L (sv) * | 1990-11-21 | 1992-05-22 | Eva Greijer | Metoder foer immobilisering av liposomer i gelkulor, och gelkulor med liposomer vilka immobiliserats med anvaendning av dessa metoder |
CN1160582A (zh) * | 1996-12-27 | 1997-10-01 | 暨南大学生物工程研究所 | 含有细胞生长因子的皮肤外用组合物 |
WO2001015750A1 (en) * | 1999-08-27 | 2001-03-08 | Department Of National Defence | Hydrogel wound dressing containing liposome-encapsulated therapeutic agent |
CN1163218C (zh) * | 1999-09-10 | 2004-08-25 | 广州市华桑生物工程有限公司 | 新型护肤化妆品 |
DE10042576B4 (de) * | 2000-08-15 | 2004-08-12 | Coty B.V. | Kosmetischer Basiskomplex und dessen Verwendung |
EP3015101B1 (en) * | 2005-10-03 | 2019-08-21 | PINSKY, Mark A. | Non-phospholipid liposomes comprising hyaluronic acid |
JP2007224012A (ja) * | 2006-01-30 | 2007-09-06 | Fujifilm Corp | 酵素架橋したタンパク質ナノ粒子 |
EP1894477B1 (en) * | 2006-08-31 | 2009-07-15 | Nestec S.A. | Food protein and charged emulsifier interaction |
JP2008133195A (ja) * | 2006-11-27 | 2008-06-12 | Konica Minolta Holdings Inc | 水溶性薬剤内包リポソーム及びその製造方法 |
KR100924643B1 (ko) * | 2007-10-12 | 2009-11-02 | 세원셀론텍(주) | 아텔로콜라겐을 포집한 리포좀의 제조방법 |
JP2009191004A (ja) * | 2008-02-14 | 2009-08-27 | Pars Co Ltd | 成長因子を含有するリポソームを含む皮膚外用剤及びその製造方法 |
JP2009249370A (ja) * | 2008-04-11 | 2009-10-29 | Fujifilm Corp | タンパク質ナノ粒子 |
MX2011000047A (es) * | 2008-06-30 | 2011-06-16 | Orf Liftaekni Hf | Uso de factores de crecimiento recombinantes derivados de plantas en el cuidado de la piel. |
JP5757563B2 (ja) * | 2011-05-13 | 2015-07-29 | 株式会社ツツミプランニング | 化粧料 |
US9603800B2 (en) * | 2012-04-12 | 2017-03-28 | Yale University | Methods of treating inflammatory and autoimmune diseases and disorders using nanolipogels |
-
2015
- 2015-03-27 JP JP2015067361A patent/JP6522387B2/ja active Active
-
2016
- 2016-03-28 WO PCT/JP2016/059983 patent/WO2016158883A1/ja active Application Filing
- 2016-03-28 CN CN201680016786.3A patent/CN107405279A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN107405279A (zh) | 2017-11-28 |
JP2016185933A (ja) | 2016-10-27 |
WO2016158883A1 (ja) | 2016-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6522387B2 (ja) | ハイドロゲル含有化粧料 | |
Anwekar et al. | Liposome-as drug carriers. | |
Mitkari et al. | Formulation and evaluation of topical liposomal gel for fluconazole | |
Gonzalez-Rodriguez et al. | Charged liposomes as carriers to enhance the permeation through the skin | |
Akhtar | Vesicles: a recently developed novel carrier for enhanced topical drug delivery | |
US7951396B2 (en) | Preparation of nanoliposome-encapsulating proteins and protein-encapsulated nanoliposome | |
JP5226693B2 (ja) | ミトコンドリア機能の改善のためのカルジオリピン含有リポソーム | |
CN103906503A (zh) | 用于无菌制备脂质-核酸颗粒的单次使用系统 | |
ES2754523T3 (es) | Composiciones estimulantes de células madre | |
CN104755096B (zh) | 重构的hdl配制剂 | |
US20080138392A1 (en) | Liposome containing cardiolipin for improvement of mitochondrial function | |
EP3241565A2 (en) | Hybrid-type multi-lamellar nanostructure of epidermal growth factor and liposome and method for manufacturing same | |
Chen et al. | Long-lasting insulin treatment via a single subcutaneous administration of liposomes in thermoreversible pluronic® F127 based hydrogel | |
Matharoo et al. | Transferosomes as a transdermal drug delivery system: Dermal kinetics and recent developments | |
Maurya et al. | Enhanced transdermal delivery of indinavir sulfate via transfersomes | |
Tian et al. | Co-delivery of bioactive peptides by nanoliposomes for promotion of hair growth | |
WO2023237004A1 (zh) | 一种三元冻干组合物及其在冻干制剂中的应用 | |
CN100566810C (zh) | 用脂质膜被覆粒子的方法 | |
RU2320323C1 (ru) | Система доставки биологически активных веществ с помощью ниосом | |
JP5916743B2 (ja) | ヘモグロビン含有リポソーム及びその製法 | |
CN117100871A (zh) | 一种用于保护生物来源的细胞外囊泡的医用级储存制剂及其应用 | |
JP6735426B2 (ja) | カチオン化ベシクル及びその組成物 | |
Sanarova et al. | Liposome drug delivery | |
CN102552149B (zh) | 一种注射用肝素钙脂质体制剂 | |
JP2678138B2 (ja) | 牛乳を含むo/w型エマルジョン化粧料組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170929 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180731 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180927 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181129 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190402 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190424 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6522387 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |